GLP-1 receptor agonists show little effect on obesity-related cancer risk
1. In this systematic review and meta-analysis, use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was not associated with a significant ...
Tag: pancreatic cancer
mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial
1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotecan and oxaliplatin ...
Artificial Intelligence and Real World Data Speed Up Drug Development
Key points:1. TriNetX is using real world data to reduce clinical trial enrollment time by as much as 40 percent2. ...
#VisualAbstract: Cabozantinib Improved Progression-Free Survival in Advanced Neuroendocrine 2m -m Tumors
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
The 2 Minute Medicine Podcast Episode 16
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
The Scan by 2 Minute Medicine®: Over the Counter Birth Control, The Promise of the Pancreatic Cancer Vaccine, and Montana Bans TikTok!
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
Preoperative biliary draining prior to pancreaticoduodenectomy not associated with increased complication risk
1. In patients with a pancreatic or periampullary tumour undergoing pancreaticoduodenectomy (PD), this retrospective study found no difference in surgical ...
Polycystic ovarian syndrome is associated with an increased risk of pancreatic cancer
1. Polycystic ovarian syndrome (PCOS) diagnosis puts women at 1.9 times higher risk of pancreatic cancer 2. PCOS was an ...
#VisualAbstract: Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
